Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arcoma ABOSTO:ARCOMA -1.40%75 PB Ratio is 1.60 as of Jul. 18, 2026, which is 42% below its 10-year median of 2.76. GuruFocus rates OSTO:ARCOMA with a GF Score™ of 75/100 and a GF Value™ of kr7.87 (Fairly Valued). The stock has 1 warning sign investors should review. Among 787 Medical Devices & Instruments companies, Arcoma AB ranks better than 60.1% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-18), Arcoma AB's share price is kr8.44. Arcoma AB's Book Value per Share for the quarter that ended in Mar. 2026 was kr5.28. Hence, Arcoma AB's PB Ratio of today is 1.60.
Good Sign:
Arcoma AB stock PB Ratio (=1.53) is close to 5-year low of 1.38.
The historical rank and industry rank for Arcoma AB's PB Ratio or its related term are showing as below:
OSTO:ARCOMA'
s PB Ratio Range Over the Past 10 Years
Min: 1.05 Med: 2.76 Max: 7.87
Current: 1.62
During the past 13 years, Arcoma AB's highest PB Ratio was 7.87. The lowest was 1.05. And the median was 2.76.
OSTO:ARCOMA's PB Ratio is ranked better than 60.1% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs OSTO:ARCOMA: 1.62
During the past 12 months, Arcoma AB's average Book Value Per Share Growth Rate was 13.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 14.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 1.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Arcoma AB was 254.50% per year. The lowest was -81.10% per year. And the median was 3.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Arcoma AB PB Ratio Related Terms
Arcoma AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Arcoma AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Arcoma AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcoma AB PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Arcoma AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Arcoma AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Arcoma AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Arcoma AB (OSTO:ARCOMA) has a PB Ratio of 1.60 as of Jul. 18, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Arcoma AB and its competitors. This is 42% below median its historical median of 2.76. Over the past decade, Arcoma AB's PB Ratio has ranged from 1.05 to 7.87. According to the industry distribution chart, Arcoma AB ranks #314 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 39.9%.
Is Arcoma AB's PB Ratio too high?
Arcoma AB's current PB Ratio of 1.60 is 42% below median its 10-year median of 2.76. Over the past 10 years, this metric has ranged from a low of 1.05 to a high of 7.87. The Medical Devices & Instruments industry median PB Ratio is 2.05. Arcoma AB's value of 1.60 is 22% below this industry median. Based on the distribution chart, Arcoma AB ranks #314 out of 787 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Arcoma AB has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arcoma AB's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Arcoma AB ranks #314 out of 787 companies for PB Ratio. This puts Arcoma AB in the upper half of its industry. The industry median PB Ratio is 2.05. Arcoma AB's value of 1.60 is 22% below this benchmark. Historically, Arcoma AB's own PB Ratio has ranged from 1.05 to 7.87 over the past decade. While the company's 10-year median is 2.76 vs. the industry median of 2.05, Arcoma AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcoma AB's current PB Ratio of 1.60 is 22% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Arcoma AB and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcoma AB's current PB Ratio is 1.60, which is 42% below median its own 10-year median of 2.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcoma AB stock overvalued right now?
Based on GuruFocus' analysis, Arcoma AB (OSTO:ARCOMA) is currently considered Fairly Valued. The stock's GF Value™ is kr7.87, compared to a current price of kr8.44 — trading 7.2% above its estimated fair value. The current PB Ratio is 1.60, which is 42% below median its 10-year median of 2.76 and 22% below the Medical Devices & Instruments industry median of 2.05. Arcoma AB's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Arcoma AB (OSTO:ARCOMA), the current PB Ratio is 1.60 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcoma AB (OSTO:ARCOMA) Overvalued in 2026?
Based on GuruFocus' analysis, Arcoma AB stock appears to be overvalued.
The current stock price of kr8.44 is trading 7.2% above its estimated GF Value™ of kr7.87.
GuruFocus considers Arcoma AB to be Fairly Valued.
Key valuation signals for OSTO:ARCOMA:
PB Ratio: 1.60 (42% below median its 10-year median of 2.76)
GF Value™: kr7.87 vs. price of kr8.44 (7.2% above fair value)
Industry Position: 22% below the Medical Devices & Instruments median (#314 of 787)
No single metric tells the full story. See the OSTO:ARCOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcoma AB provides digital radiography systems in Sweden. It offers products including wireless flat panel detectors, positioning devices, and precision dr systems.
75GF Score
Get the complete analysis for OSTO:ARCOMA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ARCOMA has been successfully added to your 
